AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT. Like some of the first-generation immune checkpoints (e.g., PD-1 and CTLA-4), TIGIT is expressed on exhausted T cells, which may reside inside tumors but are unable to mount an effective attack against the cancer cells.
It is also expressed on a wide range of other tumor-infiltrating immune cells, such as NK cells and regulatory T cells. By producing proteins that bind to TIGIT, cancer and other cells can interfere with the ability of tumor-infiltrating immune cells to mount an effective anti-tumor response. AB154 will block this interaction, which we expect will result in a powerful anti-tumor effect. A Phase 1 trial initiated to evaluate AB154 as monotherapy and in combination with AB122. The dose-escalation portion to be followed by expansion cohorts in tumor types with high levels of TIGIT and/or CD155 (TIGIT’s ligand)
AB154 Clinical Trials
A Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with AB122 in participants with advanced solid malignancies.
Publications and Abstracts
November 7-November 11, 2018
Preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapies. Anderson AE, Udyavar A, Becker A, Seitz L, Singh H, Zhao X, Walker NPC, Walters MJ, Tan JBL Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P697; abstract No. 10538.
September 30-October 3, 2018
Preclinical characterization of AB154, a fully humanized a-TIGIT antibody, for use in combination therapies Anderson AE, Becker A, Yin F, Singh H, Zhao X, Seitz L, Stanton R, Walker NPC, Tan J. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; New York, New York; abstract No. A124.